Harrow Health, Inc. (HROW)
| Market Cap | 260.33M |
| Revenue (ttm) | 62.57M |
| Net Income (ttm) | 7.05M |
| Shares Out | 26.89M |
| EPS (ttm) | 0.27 |
| PE Ratio | 35.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,319 |
| Open | 9.81 |
| Previous Close | 9.82 |
| Day's Range | 9.52 - 9.85 |
| 52-Week Range | 4.65 - 11.24 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 15.13 (+56.3%) |
| Est. Earnings Date | Nov 8, 2021 |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the devel...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 15.13, which is an increase of 56.30% from the latest price.
News
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company develop...
Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum
For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free triamcin...
Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.
NASHVILLE, Tenn. & TOKYO--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pha...
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Ch...
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health: Q2 Earnings Insights
Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results. Quarterly Results Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0...
Harrow Health Announces Second Quarter 2021 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June...
What's in Store for Harrow Health (HROW) in Q2 Earnings?
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow Health (HROW) Gains As Market Dips: What You Should Know
In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.
Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year?
Is (HROW) Outperforming Other Medical Stocks This Year?
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)---- $HROW--Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the secon...
NovaBay Pharmaceuticals Partners with Harrow Health's ImprimisRx® to Promote Prescription Avenova
EMERYVILLE, Calif. & NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW #Avenova--NovaBay partners with ImprimisRx to promote prescription Avenova.
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)
The heavy selling pressure might have exhausted for Harrow (HROW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re...
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
Harrow (HROW) Surges 12%: Is This an Indication of Further Gains?
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its un...
Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its un...
Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones
NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced...
Harrow Health: Return On Capital Employed Insights
Harrow Health (NASDAQ:HROW) posted a 7.77% decrease in earnings from Q4. Sales, however, increased by 5.81% over the previous quarter to $15.44 million.
Harrow Health Launches New Corporate and Investor Website
NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its new...
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx's Proprietary Klarity-C® Drops
Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease Multi-center Retrospective Study Demonstrates Statistically Significant Reducti...
Recap: Harrow Health Q1 Earnings
Shares of Harrow Health (NASDAQ:HROW) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 102.00% year over year to $0.01, which beat ...
Harrow Health Announces Record First Quarter 2021 Financial Results
Highlights for First Quarter 2021: